Evidence map›Paper›PMID 42062555›Full record

ArticleLeukemia2026

How should myelodysplastic neoplasms with isolated deletion 5q and TP53 multihit alterations be classified?

Maria Julia Montoro, Pamela Acha, Claudia Haferlach, Onyee Chan, Víctor Navarro, Yasuo Kubota, Felicitas Schulz, Robert Briski, Najla H Al Ali, Blanca Xicoy and 39 more

Abstract read
PubMed Publisher
In one paragraph

Article in Leukemia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Lenalidomide Exposure andCurrent oncology (Toronto, Ont.) · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

49 authors.

Maria Julia MontoroDepartment of Hematology, Vall d'Hebron Institute of Oncology, University Hospital Vall d'Hebron, Barcelona, Spain.
Pamela AchaDepartment of Hematology, Vall d'Hebron Institute of Oncology, University Hospital Vall d'Hebron, Barcelona, Spain.
Claudia HaferlachMLL Munich Leukemia Laboratory, Munich, Germany.ORCID http://orcid.org/0000-0002-6333-5049
Onyee ChanDepartment of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, USA.ORCID http://orcid.org/0000-0003-2872-1961
Víctor NavarroStatistics Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.ORCID http://orcid.org/0000-0001-6925-4605
Yasuo KubotaDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.ORCID http://orcid.org/0000-0002-7909-5422
Felicitas SchulzDepartment of Hematology, Oncology and Clinical Immunology, University Medical Center Düsseldorf, Heinrich-Heine-University, Düsseldorf, Germany.
Robert BriskiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0009-0008-7975-8223
Najla H Al AliDepartment of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, USA.
Blanca XicoyDepartment of Hematology, Institut Català Oncologia-Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Badalona, Universitat Autònoma de Barcelona, Barcelona, Spain.ORCID http://orcid.org/0000-0002-0295-1307
Laura PalomoDepartment of Hematology, Vall d'Hebron Institute of Oncology, University Hospital Vall d'Hebron, Barcelona, Spain.
Felix López-CadenasDepartment of Hematology, Hospital del Mar, Barcelona, Spain.
Francesc BoschDepartment of Hematology, Vall d'Hebron Institute of Oncology, University Hospital Vall d'Hebron, Barcelona, Spain.ORCID http://orcid.org/0000-0001-9241-2886
Manja MeggendorferMLL Munich Leukemia Laboratory, Munich, Germany.ORCID http://orcid.org/0000-0002-9038-3265
Teresa GonzálezDepartment of Hematology, Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain.
Lea Naomi EderClinics of Hematology and Medical Oncology, University Medical Center Göttingen, Georg-August- University, Göttingen, Germany.
Andrés JerezDepartment of Hematology, Vall d'Hebron Institute of Oncology, University Hospital Vall d'Hebron, Barcelona, Spain.
YuHung WangDivision of Cancer Sciences, Epigenetics of Haematopoiesis Laboratory, The University of Manchester, Manchester, UK.
Alessia CampagnaHumanitas Research Hospital and Department of Biomedical Sciences, Humanitas University, Milan, Italy IRCCS Humanitas Research Hospital-Rozzano, Milan, Italy.
Beate BetzDepartment of Hematology, Oncology and Clinical Immunology, University Medical Center Düsseldorf, Heinrich-Heine-University, Düsseldorf, Germany.
Valeria SantiniMDS Unit, Hematology, AOUC, University of Florence, Florence, Italy.ORCID http://orcid.org/0000-0002-5439-2172
Teresa BernalHospital Universitario Central de Asturias, Instituto Universitario (IUOPA), Instituto de Investigación del Principado de Asturias (ISPA), Oviedo, Spain.
Esperanza SuchDepartment of Hematology, Servicio de Hematología, Hospital La Fe, Valencia, Spain.
Anne Sophie PlatzbeckerDepartment of Hematology, University Hospital of Leipzig, Dresden, Germany.ORCID http://orcid.org/0000-0002-0747-4941
Tariq KewanYale University and Yale Cancer Center, New Haven, CT, USA.
Carmelo GurnariDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.ORCID http://orcid.org/0000-0001-6829-5544
Carla ZindelService d'Hématologie Séniors, Hôpital Saint-Louis, Universite de Paris 7, Paris, France.
Austin KulasekararajKing's College Hospital NHS Foundation Trust, London, UK.ORCID http://orcid.org/0000-0003-3180-3570
Maria Teresa VosoDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.ORCID http://orcid.org/0000-0002-6164-4761
Mikkael SekeresDivision of Hematology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.ORCID http://orcid.org/0000-0003-2009-6524
Nicolas Díaz-VarelaHospital Universitario Central de Asturias, Instituto Universitario (IUOPA), Instituto de Investigación del Principado de Asturias (ISPA), Oviedo, Spain.
Aref Al-KaliDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Antonella PoliniHematology Clinic, Azienda Ospedaliera Universitaria delle Marche, Università Politecnica delle Marche, Ancona, Italy.
Elisa DiralSan Raffaele Scientific Institute, Milano, Italy.
Mara MemoliFederico II University Medical School, Naples, Italy.
Uwe PlatzbeckerDepartment of Hematology, University Hospital of Leipzig, Dresden, Germany.
Detlef HaaseDepartment of Hematology, Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain.
Amer M ZeidanYale University and Yale Cancer Center, New Haven, CT, USA.ORCID http://orcid.org/0000-0001-7017-8160
María Díez-CampeloDepartment of Hematology, Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain.
Guillermo Garcia-ManeroDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-3631-2482
Daniel H WisemanDivision of Cancer Sciences, Epigenetics of Haematopoiesis Laboratory, The University of Manchester, Manchester, UK.ORCID http://orcid.org/0000-0003-0715-1402
Matteo G Della PortaHumanitas Research Hospital and Department of Biomedical Sciences, Humanitas University, Milan, Italy IRCCS Humanitas Research Hospital-Rozzano, Milan, Italy.
Ulrich GermingDepartment of Hematology, Oncology and Clinical Immunology, University Medical Center Düsseldorf, Heinrich-Heine-University, Düsseldorf, Germany.
Jaroslaw MaciejewskiDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.ORCID http://orcid.org/0000-0002-6837-4346
Rami S KomrokjiDepartment of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, USA.ORCID http://orcid.org/0000-0002-1876-5269
Francesc SoléMyelodysplastic Syndromes Research Group, Josep Carreras Leukaemia Research Institute, Barcelona, Spain.ORCID http://orcid.org/0000-0002-3251-2161
Torsten HaferlachMLL Munich Leukemia Laboratory, Munich, Germany.
Pierre FenauxService d'Hématologie Séniors, Hôpital Saint-Louis, Universite de Paris 7, Paris, France.
David ValcárcelDepartment of Hematology, Vall d'Hebron Institute of Oncology, University Hospital Vall d'Hebron, Barcelona, Spain. dvalcarcel@vhio.net.ORCID http://orcid.org/0000-0002-8747-078X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myelodysplastic neoplasms (MDS) with TP53 multihit alterations are associated with dismal outcomes. MDS with isolated del(5q) present favorable prognosis but is defined by the absence of TP53 multihit alterations. However, whether TP53 multihit alterations exert the same adverse impact in this genetic context remains uncertain. We retrospectively analyzed the characteristics and outcome of 43 patients with MDS with isolated del(5q) harboring TP53 multihit alterations (MDS-del(5q) TP53 multihit) and compared with 68 patients with low-blast MDS with TP53 multihit and without isolated del(5q) (MDS-LB TP53 multihit). Patients with MDS-del(5q) TP53 multihit showed significantly higher platelet counts, more frequent SF3B1 mutations, were less often classified as high-risk by IPSS-R or IPSS-M, and had significantly better outcomes than patients with MDS-LB TP53 multihit: overall survival of 70.2 vs 13.9 months, and time to acute myeloid leukemia progression (AML) of 31.9 vs 7.2 months, respectively. Moreover, the superior outcomes of MDS-del(5q) TP53 multihit patients persisted significant even when compared with MDS-LB TP53 multihit cases without complex karyotype (survival of 70.2 vs 39.9 months; time to AML progression of 31.9 vs 11.4 months). These findings indicate that, in MDS-del(5q) the adverse impact of TP53 multihit alterations may be less important than in other MDS subtypes.

Indexed as

Chromosome DeletionChromosomes, Human, Pair 5MutationMyelodysplastic SyndromesTumor Suppressor Protein p53AgedAged, 80 and overFemaleHumansMaleMiddle AgedPhosphoproteinsPrognosisRetrospective StudiesRNA Splicing FactorsPhosphoproteinsRNA Splicing FactorsSF3B1 protein, humanTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID42062555

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.